Pfizer, BioNTech to collaborate in developing mRNA-based shingles vaccine

Shares of Pfizer Inc. /zigman2/quotes/202877789/composite PFE +0.50% rose 1.6% in premarket trading Wednesday and BioNTech SE /zigman2/quotes/214419716/composite BNTX +6.88% gained 0.9%, after the drug makers said they will collaborate in developing a potential first mRNA-based shingles vaccine. The companies said they will leverage the antigen technology identified by Pfizer and BioNTech's mRNA platform technology, which were used to develop their COVID-19 vaccine. Clinical trials of the potential shingles vaccine are expected to start in the second half of 2022. Under terms of the collaboration agreement, Pfizer will make upfront payments of $225 million to BioNTech, including a $75 million cash payment and $150 million equity investment, while BioNTech will pay Pfizer $25 million for its antigen technology. BioNTech will be eligible to receive regulatory and sales milestone payments of up to $200 million. Pfizer's stock has rallied 46.6% over the past 12 months and BioNTech shares have soared 158.2%, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -0.58% has advanced 28.6%.

/zigman2/quotes/202877789/composite

Add to watchlist PFE

Pfizer Inc.

US : U.S.: NYSE

$ 50.65

+0.25 +0.50%

Volume: 19.87M

May 19, 2022 4:03p

P/E Ratio

11.62

Dividend Yield

3.16%

Market Cap

$284.65 billion

Rev. per Employee

$1.17M

/zigman2/quotes/214419716/composite

Add to watchlist BNTX

BioNTech SE ADR

US : U.S.: Nasdaq

$ 167.87

+10.81 +6.88%

Volume: 1.82M

May 19, 2022 4:00p

P/E Ratio

3.52

Dividend Yield

0.91%

Market Cap

$38.17 billion

Rev. per Employee

$7.28M

/zigman2/quotes/210599714/realtime

Add to watchlist SPX

S&P 500 Index

US : S&P US

3,900.79

-22.89 -0.58%

Volume: 2.77B

May 19, 2022 4:57p